ArticleBlood neoplasia2026

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Adam J Olszewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.